Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.

The GlaxoSmithKline and Celgene-backed immunotherapy developer has revealed its intention to float on the Nasdaq Global Market.

The Pfizer, GlaxoSmithKline, Novartis, AbbVie and Astellas-backed oncology therapy developer is set to go public through a reverse takeover.

The payment software provide's shared popped on their first day after an IPO that followed two Goldman Sachs-backed funding rounds.

AMTD Group is looking to spin off its digital financial services arm, which counts Maoyan Entertainment as an investor, through an initial public offering in the United States.

UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.

Columbia’s Text IQ has been bought by Relativity for an undisclosed amount.

Affirm spinoff Resolve raised $60m from investors including its parent company, while sales and marketing software provider Qualified secured $51m in a Salesforce-backed round.

Uniqa is set to exit the mobile payment and lending app operator in an acquisition by Zip, which has agreed to pay $68.8m for the remaining shares after it had co-led the latter’s January 2021 round.

Lund spinout Glō has agreed to an acquisition by Nanosys, which will now look to strengthen its market share in TV sets and enter more markets such as AR.